Press Releases
March 3, 2016
Dr. Dalvir S. Gill Appointed to Sun BioPharma Board of Directors
January 6, 2016
Dosing of First Patient in Phase 1 Clinical Study of SBP-101 for Pancreatic Cancer
November 16, 2015
Q3 2015 Earnings Release
Sun BioPharma Files Form 10-Q for Third Quarter 2015 and Provides Business Update
November 9, 2015
Compelling Preclinical Data on Sun BioPharma’s SBP-101 Presented at APA Annual Meeting
October 26, 2015
Sun BioPharma to Present Three Abstracts at the 2015 American Pancreatic Association (APA) Annual Meeting
Presentations to Focus on Pre-Clinical Data for Company’s Lead Development Candidate, SBP-101, for the Treatment of Pancreatic Diseases
October 2, 2015
Scott Kellen Appointed Chief Financial Officer of Sun BioPharma
Healthcare Executive Brings Extensive Public Company Financial Experience to Leadership Team
September 30, 2015
J. Robert Paulson and Jeffrey Mathiesen Appointed to Board of Directors
Two Experienced Healthcare Executives Join Board as Company Prepares to Enroll First Patient in Phase 1 Clinical Trial
September 16, 2015
David Kaysen Named President & CEO of Sun BioPharma
Healthcare Executive Brings Extensive Clinical & Public Markets Experience to Sun’s Management Team
September 9, 2015
Sun BioPharma Adopts OTCPink Symbol SNBP
Company’s clinical development program focuses on novel approach to treatment of pancreatic cancer
August 31, 2015
U.S. FDA Grants IND for SBP-101
Phase 1 Clinical Study Expected to Begin By End of Year
Events & Presentations